Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 292

1.

Managing tumor angiogenesis: lessons from VEGF-resistant tumors and wounds.

Cuevas I, Boudreau N.

Adv Cancer Res. 2009;103:25-42. doi: 10.1016/S0065-230X(09)03002-4. Review.

PMID:
19854351
2.

III. Angiogenesis: complexity of tumor vasculature and microenvironment.

Furuya M, Yonemitsu Y, Aoki I.

Curr Pharm Des. 2009;15(16):1854-67. Review.

PMID:
19519428
3.

Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.

Shojaei F, Ferrara N.

Drug Resist Updat. 2008 Dec;11(6):219-30. doi: 10.1016/j.drup.2008.09.001. Epub 2008 Oct 23. Review.

PMID:
18948057
4.

Mathematical modeling of capillary formation and development in tumor angiogenesis: penetration into the stroma.

Levine HA, Pamuk S, Sleeman BD, Nilsen-Hamilton M.

Bull Math Biol. 2001 Sep;63(5):801-63. Erratum in: Bull Math Biol 2002 Mar;64(2):423.

PMID:
11565406
5.

Tumor angiogenesis: biology and therapeutic prospects.

Harris SR, Thorgeirsson UP.

In Vivo. 1998 Nov-Dec;12(6):563-70. Review.

PMID:
9891218
6.

Tumor angiogenesis and therapy.

Cao Y.

Biomed Pharmacother. 2005 Oct;59 Suppl 2:S340-3. Review.

PMID:
16507405
7.

Targeting tumor angiogenesis.

Gaur P, Bose D, Samuel S, Ellis LM.

Semin Oncol. 2009 Apr;36(2 Suppl 1):S12-9. doi: 10.1053/j.seminoncol.2009.02.002.

PMID:
19393831
8.
9.

Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors.

Crawford Y, Ferrara N.

Methods Enzymol. 2008;445:125-39. doi: 10.1016/S0076-6879(08)03006-1.

PMID:
19022058
10.

A pharmacologically based multiscale mathematical model of angiogenesis and its use in investigating the efficacy of a new cancer treatment strategy.

Billy F, Ribba B, Saut O, Morre-Trouilhet H, Colin T, Bresch D, Boissel JP, Grenier E, Flandrois JP.

J Theor Biol. 2009 Oct 21;260(4):545-62. doi: 10.1016/j.jtbi.2009.06.026. Epub 2009 Jul 15.

PMID:
19615383
11.

[VEGF, anti-vEGF and diseases].

Corvol P.

Bull Acad Natl Med. 2008 Feb;192(2):289-300; discussion 300-2. Review. French.

PMID:
18819684
12.

VEGF inhibition: insights from preclinical and clinical studies.

Crawford Y, Ferrara N.

Cell Tissue Res. 2009 Jan;335(1):261-9. doi: 10.1007/s00441-008-0675-8. Epub 2008 Sep 3. Review.

PMID:
18766380
13.

VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy.

Greenberg JI, Cheresh DA.

Expert Opin Biol Ther. 2009 Nov;9(11):1347-56. doi: 10.1517/14712590903208883. Review.

PMID:
19761418
14.

Use of angiogenesis inhibitors in tumour treatment.

Fayette J, Soria JC, Armand JP.

Eur J Cancer. 2005 May;41(8):1109-16. Review.

PMID:
15911233
15.

On the role of endothelial progenitor cells in tumor neovascularization.

Komarova NL, Mironov V.

J Theor Biol. 2005 Aug 7;235(3):338-49.

PMID:
15882696
16.

Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.

Shibuya M.

FEBS J. 2009 Sep;276(17):4636-43. doi: 10.1111/j.1742-4658.2009.07175.x. Epub 2009 Jul 31. Review.

17.

Vascular changes in hepatocellular carcinoma.

Yang ZF, Poon RT.

Anat Rec (Hoboken). 2008 Jun;291(6):721-34. doi: 10.1002/ar.20668. Review.

18.

Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.

De Bock K, Cauwenberghs S, Carmeliet P.

Curr Opin Genet Dev. 2011 Feb;21(1):73-9. doi: 10.1016/j.gde.2010.10.008. Epub 2010 Nov 22. Review.

PMID:
21106363
19.

Manipulating angiogenesis in medicine.

Carmeliet P.

J Intern Med. 2004 May;255(5):538-61. Review.

20.

Pathways mediating VEGF-independent tumor angiogenesis.

Ferrara N.

Cytokine Growth Factor Rev. 2010 Feb;21(1):21-6. doi: 10.1016/j.cytogfr.2009.11.003. Epub 2009 Dec 11. Review.

PMID:
20005148

Supplemental Content

Support Center